Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 6:12:e44875.
doi: 10.2196/44875.

Investigating the Secondary Use of Clinical Research Data: Protocol for a Mixed Methods Study

Naomi Waithira  1   2 , Evelyne Kestelyn  1   3 , Keitcheya Chotthanawathit  2 , Anne Osterrieder  1 , Mavuto Mukaka  1   2 , Trudie Lang  1 , Phaik Yeong Cheah  1   2
Affiliations

Investigating the Secondary Use of Clinical Research Data: Protocol for a Mixed Methods Study

Naomi Waithira et al. JMIR Res Protoc. .

Abstract

Background: The increasing emphasis to share patient data from clinical research has resulted in substantial investments in data repositories and infrastructure. However, it is unclear how shared data are used and whether anticipated benefits are being realized.

Objective: The purpose of our study is to examine the current utilization of shared clinical research data sets and assess the effects on both scientific research and public health outcomes. Additionally, the study seeks to identify the factors that hinder or facilitate the ethical and efficient use of existing data based on the perspectives of data users.

Methods: The study will utilize a mixed methods design, incorporating a cross-sectional survey and in-depth interviews. The survey will involve at least 400 clinical researchers, while the in-depth interviews will include 20 to 40 participants who have utilized data from repositories or institutional data access committees. The survey will target a global sample, while the in-depth interviews will focus on individuals who have used data collected from low- and middle-income countries. Quantitative data will be summarized by using descriptive statistics, while multivariable analyses will be used to assess the relationships between variables. Qualitative data will be analyzed through thematic analysis, and the findings will be reported in accordance with the COREQ (Consolidated Criteria for Reporting Qualitative Research) guidelines. The study received ethical approval from the Oxford Tropical Research Ethics Committee in 2020 (reference number: 568-20).

Results: The results of the analysis, including both quantitative data and qualitative data, will be available in 2023.

Conclusions: The outcomes of our study will offer crucial understanding into the current status of data reuse in clinical research, serving as a basis for guiding future endeavors to enhance the utilization of shared data for the betterment of public health outcomes and for scientific progress.

Trial registration: Thai Clinical Trials Registry TCTR20210301006; https://tinyurl.com/2p9atzhr.

International registered report identifier (irrid): DERR1-10.2196/44875.

Keywords: artificial intelligence; barriers; clinical research; clinical trials data; data reuse; data sharing; individual patient data; low- and middle-income country; machine learning; mixed methods; online survey; secondary data use.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Wilkinson T, Sinha S, Peek N, Geifman N. Clinical trial data reuse - overcoming complexities in trial design and data sharing. Trials. 2019 Aug 19;20(1):513. doi: 10.1186/s13063-019-3627-6. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3627-6 10.1186/s13063-019-3627-6 - DOI - PMC - PubMed
    1. Coady SA, Mensah GA, Wagner EL, Goldfarb ME, Hitchcock DM, Giffen CA. Use of the National Heart, Lung, and Blood Institute Data Repository. N Engl J Med. 2017 May 11;376(19):1849–1858. doi: 10.1056/NEJMsa1603542. https://europepmc.org/abstract/MED/28402243 - DOI - PMC - PubMed
    1. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Sugiarto P, Tjitra E, Anstey NM, Price RN. Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malar J. 2015 Jul 15;14:272. doi: 10.1186/s12936-015-0794-0. https://malariajournal.biomedcentral.com/articles/10.1186/s12936-015-0794-0 10.1186/s12936-015-0794-0 - DOI - PMC - PubMed
    1. Kieny M, Salama P. WHO R&D Blueprint: a global coordination mechanism for R&D preparedness. Lancet. 2017 Jun 24;389(10088):2469–2470. doi: 10.1016/S0140-6736(17)31635-5.S0140-6736(17)31635-5 - DOI - PubMed
    1. World Health Organization Targeted update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19. World Health Organization. [2023-02-17]. https://cdn.who.int/media/docs/default-source/blue-print/targeted-update... .

LinkOut - more resources